Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > September expectations

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Aug 15, 2022 4:23pm

89 Views

Post# 34897562

RE:September expectations

"Quite simple to deliver"
Can u expand ?

Joemare wrote: P1 efficacy data in sortilin overexpressed cancer types (in at least 2 cancer types)
Assurance or at least a path to assurance, that the efficacy effect is that of Th1902.

Quite simple to deliver.

Leadership is also showing up at cancer trial sites and making sure the P.I. is focused on patient accrual.